|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
The Bioterrorism Act
Author(s)Arthur J. Falk, PhD
Two FDA final rules issued in response to the Bioterrorism Response Act of 2002 may significantly affect the supply and importation of pharmaceutical excipients.
Advertisement
Articles in this issue
over 22 years ago
Coprocessed Excipients for Solid Dosage Formsover 22 years ago
Manufacturing Execution Systemsover 22 years ago
State-of-the-Art Packaging Machinesover 22 years ago
January 2004over 22 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersover 22 years ago
New Supply-Chain Dynamicsover 22 years ago
In the Spotlight--February 2004over 22 years ago
January 2004Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Oral Solid Dosage Validation Is a Business Continuity Function, Not Just a Compliance Requirement
2
Technology Transfer: Success Drivers and Obstacles Explained
3
Managing Global Trial Supply Risk: Expert Insights
4
How to Vet Importer of Record Partners for Clinical Trials
5